Gilead Makes Virology Bet with MYR Buy
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 15 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2578 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Gilead Sciences has agreed to acquire MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialisation of therapeutics for the treatment of chronic hepatitis delta virus (HDV)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS